SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (145)11/24/2000 12:31:49 PM
From: tommysdad   of 1784
 
<<I'm curious as to why you don't like 'em>>

IMHO, there is little evidence that there is any value added to what they do. And I don't think there is quality there.

I don't think there is any compelling evidence that vast numbers of compounds of questionable quality will help you find drugs faster. Crappy leads that will never be turned into drugs: yes. Small molecules that will burn biology and chemistry resources indefinitely: yes. Actual marketable drugs: no.

Think about it: all of these combichem companies promised reduced time to the clinic and faster validation of drug targets. They (PCOP, ARQL, TRGA, etc. etc.) have been in business long enough for one to judge the validity of those predictions.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News